Breast Cancer
Conditions
Interventions
case series:N/A
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Female patients with histologically-confirmed diagnosed with early-stage invasive breast cancer; 2. Complete clinicopathological information and follow-up until December 2020; 3. HER2 expression is measured by IHC with CFDA approved reagents.The 2013 ASCO/CAP HER2 guidelines provide standards for determining HER2 status; 4. HER2 staining showed HER2 low-expressing(IHC1 + or IHC2 + /-); 5. Patients received completion resection of primary breast tumor; 6. Patients received standard systemic treatment with reference to the Guidelines, such as Chinese Anti-Cancer Association guidelines (2013 Edition) or NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1. 2014, including adjuvant/(neoadjuvant) chemotherapy for >= 4 cycles, receiving endocrine therapy if indicated.
Exclusion criteria
Exclusion criteria: 1. First diagnosis of stage IV or metastatic breast cancer; 2. Failure to complete the expected systemic treatment; 3. Past tumor treatment history; 4. Bilateral breast cancer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease Free Survival;Overall Survival; | — |
Countries
China
Contacts
Public ContactLiu Yinhua
Peking University First Hospital
Outcome results
None listed